To get through a dense jungle, you'll need to clear a path. Similarly, to get past a thick network of scaffolding that often prevents drugs from reaching cancer cells, UCLA researchers have developed nanoparticles capable of clearing a path for drugs to pass through to a tumor.
GlaxoSmithKline's latest attempt to enlist the academic community in its translational research efforts has won a chilly reception from the upper echelon of UCLA.
Chronic or nonhealing sores or wounds can be caused by a number of factors, including diabetes, surgery, severe skin irritations, burns, traumatic accidents or impaired blood flow. As diabetes and obesity rates in the U.S. soar, these types of wounds are becoming more common, and the cost to treat them is on the rise.
A newly identified protein with virus-fighting properties could help prevent deadly pathogenic viruses, such as HIV and Ebola, among others.
Researchers at the University of California, Los Angeles, have created what could be a new way to treat cancer, combining nanotechnology with a genetic kill switch.
NanoSmart Pharmaceuticals has hooked up with UCLA to develop targeted drugs for cancer and other serious life-threatening diseases.
Designed at UCLA with the non-scientist in mind, a game allows players to separate healthy from infected blood cells to diagnose malaria.
UCLA researchers have developed a "compact and cost-effective" rapid diagnostic test designed to work with standard cellphones, R&D Magazine is reporting.
UCLA scientists engineered human blood stem cells into mature T cells that sought out and attacked the virus in tissues where it lives and grows.
Researchers are working to develop synthetic cells that could target disease and disorder, and release drugs to treat them.